The CONDOR Platform Workstreams
CONDOR is accelerating how quickly promising COVID-19 diagnostics make it into real-world use.
The CONDOR platform is divided into three clinical evaluation studies, looking at performance of diagnostics in different real-world clinical settings, and three cross-cutting studies that work across and feed into the clinical studies.
All elements of CONDOR are underpinned by an extensive patient and public Involvement strategy.
Clinical Evaluation Studies
The CONDOR platform will determine the accuracy of COVID-19 diagnostics when used by clinical staff, in different clinical environments, using samples collected from patients who have symptoms of COVID-19 or who are tested in response to a local outbreak.
Clinical evaluations will only be carried out on diagnostics which have adequate analytical performance (i.e. those which work well when assessed under controlled laboratory conditions) and which have been prioritised by the National Test Approvals Group or the Viral Detection Test Approvals Group.
Find out more using the links below.
FALCON-C19
The FALCON-C19 study covers hospital emergency departments, inpatient areas, e.g. COVID wards, acute medical units and critical care, and 'Hospital at Home Services'.
CONDOR-CH
The CONDOR-CH study is looking at rapid testing specifically in care home settings.
RAPTOR-C19
RAPTOR-C19 is focussed on community settings, such as GP surgeries and COVID-19 testing centres
Cross-cutting studies
Care Pathway Analysis
"Care pathway mapping” studies will identify where new technologies could have the most impact on patient health during the different phases of the pandemic.
Human Factors Evaluation
Analysing the interaction between people and technologies in real-world healthcare.
Analytical Performance
Evaluating which tests should be trialled in the different clinical settings and putting the right ones forward into our clinical studies.